ArticleMMWR. Morbidity and mortality weekly report2024
Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2023-June 2024.
Article in MMWR. Morbidity and mortality weekly report, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploratory analysis of predictive models in the field of myelitis: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Response to a vaccine-derived poliovirus type 1 event - Sichuan, China, 2024.BMC infectious diseases · 2026Article
- Genomic characterization of Mycoplasma bovis, Mannheimia haemolytica, and bovine viral diarrhea virus 1 from a bovine respiratory disease complex case.BMC genomic data · 2026Article
- Disease Elimination Is Not Eradication: Rethinking "Disease-Free" Certification in Global Health amid the Global Resurgence of Measles, Polio, and Cholera.Journal of epidemiology and global health · 2026Article
- Complete genome sequences of eight poliovirus Sabin 2-derived and five novel oral poliovirus 2-derived circulating vaccine-derived poliovirus (CVDPV) genomes with single-end recombination from Botswana, 2022-2023.Microbiology resource announcements · 2026Article
- Article
- VP1 molecular evolution of type 2 immunodeficiency-related vaccine-derived polioviruses (iVDPV2) in a patient with primary immunodeficiency disease (PID).Virus genes · 2026Article
- From Surgery to Endoscopy: Comprehensive Review of Bariatric Approaches in Pediatric and Adolescent Patients.Medicina (Kaunas, Lithuania) · 2026Review
- The global threat of vaccine-preventable neurological diseases.Nature reviews. Neurology · 2026Review
- Higher stability of novel live-attenuated oral poliovirus type 2 (nOPV2) despite the emergence of a neurovirulent double recombinant strain in Uganda.Nature microbiology · 2026Article
- Neutralizing human monoclonal antibodies to poliovirus map to the receptor binding site.Nature communications · 2026Article
- Spatiotemporal and clinical characterisation of acute flaccid paralysis in Uganda, 2016-2023.BMJ public health · 2026Article
- Live Attenuated Vaccines for African Swine Fever: Perspectives on Their Use and Strategic Directions.Transboundary and emerging diseases · 2026Review
- Leave no one behind: Global Analysis on monitoring childhood vaccination timeliness and catch-up using data from the WHO/UNICEF joint reporting form on Immunization.Gates open research · 2026Article
- Editorial: Eradicating polio in Pakistan and other countries in the Eastern Mediterranean region: epidemiology, surveillance, and immunization.Frontiers in public health · 2026Article
- Tracking poliovirus through wastewater: environmental surveillance insights from Haïti (2020-2023).Applied and environmental microbiology · 2025Article
- Implementation of Poliovirus Containment in Poliovirus Designated Facilities-United States, 2017-2024.Pathogens (Basel, Switzerland) · 2025Article
- Viral vector-driven trans-encapsidation of replicon RNAs as a rapid approach for the development of safe and economically attractive anti-enterovirus vaccines.bioRxiv : the preprint server for biology · 2025Article
- Recent emergence of vaccine-derived poliovirus type 2 in Senegal and virus spread to neighboring countries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Diagnostic and vaccination challenges in the PPR pre-eradication era: Identifying gaps and potential unintended consequences.Journal of advanced veterinary and animal research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Circulating vaccine-derived polioviruses (cVDPVs) can emerge and lead to outbreaks of paralytic polio as well as asymptomatic transmission in communities with a high percentage of undervaccinated children. Using data from the World Health Organization Polio Information System and Global Polio Laboratory Network, this report describes global polio outbreaks due to cVDPVs during January 2023-June 2024 and updates previous reports. During the reporting period, 74 cVDPV outbreaks were detected in 39 countries or areas (countries), predominantly in Africa. Among these 74 cVDPV outbreaks, 47 (64%) were new outbreaks, detected in 30 (77%) of the 39 countries. Three countries reported cVDPV type 1 (cVDPV1) outbreaks and 38 countries reported cVDPV type 2 (cVDPV2) outbreaks; two of these countries reported cocirculating cVDPV1 and cVDPV2. In the 38 countries with cVDPV2 transmission, 70 distinct outbreaks were reported. In 15 countries, cVDPV transmission has lasted >1 year into 2024. In Nigeria and Somalia, both countries with security-compromised areas, persistent cVDPV2 transmission has spread to neighboring countries. Delayed implementation of outbreak response campaigns and low-quality campaigns have resulted in further international spread. Countries can control cVDPV outbreaks with timely allocation of resources to implement prompt, high-quality responses after outbreak confirmation. Stopping all cVDPV transmission requires effectively increasing population immunity by overcoming barriers to reaching children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.